Syz the moment

Pharmaceutical stocks are in freefall after Trump named Robert F. Kennedy Jr. as his HHS Secretary nominee. Moderna (-30.6%), Novavax (-42.7%), and BioNTech (-11.9%) have all tumbled since the announcement as investors fear a dramatic shift in U.S. health policy. RFK Jr., who has challenged mainstream medical practices and vowed to streamline the FDA, says he'll refocus health agencies on nutrition and fighting chronic disease. Trump: "For too long, Americans have been crushed by the industrial food complex and drug companies." Source: @Breaking911 NBC, Mario Nawfal @MarioNawfal

That would be a huge news...

There are just three options to avoid a collapse: 1. Drastically increase retirement age 2. Cut pensions and healthcare 3. Skilled, educated immigration Source: Michel A.Arouet

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market. It is down -20% today and -79% from its covid all-time-high. Moderna: "Net product sales for Q2 24 were $184M, reflecting a 37% YoY decrease. This reduction aligns with the expected shift to a seasonal COVID-19 vaccine market.." Moderna had $241M in total sales in Q2 and $1.6B in total operating expenses. Adding interest income, they burned $1.27B in one quarter. Cash on balance sheet is down to $2.47B. I fully expect expect them to do large capital raise to dilute shareholders. Source: JaguarAnalytics, The Transcript

Source: Mario Nawfal

“Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on explosive growth potential in the industry…Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF. The three next largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, each of which have a weighting under 5%”. Source: CNBC, Bloomberg

Source: Bloomberg, Carl Quintanilla